Galderma has received key manufacturing license updates from the Swedish Medical Products Agency which will allow for company growth and expanded biologics capabilities. 
 
The license update follows Galderma’s good manufacturing practices (GMP) inspection of the company’s center of excellence in Uppsala, Sweden. The update enables Galderma to manufacture and perform bioanalytical testing on the company’s proprietary investigational ready-to-use liquid botulinum toxin A, RelabotulinumtoxinA (QM1114).

RelabotulinumtoxinA is a highly active, complex-free, and ready-to-use liquid botulinum toxin A with a proprietary strain. It is designed as a liquid and is part of Galderma’s injectable aesthetics portfolio. RelabotulinumtoxinA is currently being investigated globally, to expand its neuromodulator portfolio.
 
Adrian Murphy, Head of Global Operations, Galderma, said, 
 
“Our commitment to leading innovation in dermatology is reflected in our high-performance operations. These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
 
Galderma is currently expanding its center of excellence in Uppsala. The new facility is scheduled for completion by the end of 2025 and will cater to the higher demand for injectable aesthetic treatments. 

Read Next